- Exact Sciences reported **record Q3 2025 revenue of $851 million**, a **20% year-over-year increase**, driven by **22% growth in screening revenue to $666 million** and **12% growth in precision oncology revenue to $183 million**.  **[0001124140_2228652_1]** 
- **Adjusted EBITDA for Q3 2025 was $135 million**, an increase of **37% year-over-year**, with margins expanding **200 basis points to 16%**.  **[0001124140_2228652_1]** 
- The company **raised its full-year 2025 revenue guidance to between $3.22 billion and $3.235 billion** and **adjusted EBITDA guidance to between $470 million and $480 million**.  **[0001124140_2228652_1]** 
- Key developments include the launch of **CancerGuard**, a multi-cancer early detection test, and continued expansion of **Cologuard Plus** access, including contracts with Aetna and Highmark.  **[0001124140_2228652_0]** **[0001124140_2228652_2]** 
- Exact Sciences generated **$190 million in free cash flow** during Q3 2025, contributing to a year-to-date total of **$236 million**, an increase of **270% year-over-year**.  **[0001124140_2228652_1]**

Exact Sciences Reports Record Q3 2025 Results and Raises Full-Year Guidance

- Exact Sciences reported **total revenue of $850.7 million** in Q3 2025, marking a **20% increase** year-over-year.  **[0001124140_2228511:3]** **[0001124140_2228511:6]** **[0001124140_2228511:8]** 
- **Adjusted EBITDA** for Q3 2025 reached **$135.4 million**, an **increase of 37%** year-over-year, with an **adjusted EBITDA margin of 16%**.  **[0001124140_2228511:3]** **[0001124140_2228511:9]** 
- The company reported a **GAAP net loss of $(19.6) million**, or **$(0.10) per share**, in Q3 2025, an improvement from a net loss of $(38.2) million, or $(0.21) per share, in Q3 2024.  **[0001124140_2228511:6]** 
- **Free cash flow for the nine months ended September 30, 2025, was $236.3 million**.  **[0001124140_2228511:4]** **[0001124140_2228511:15]** 
- Exact Sciences **updated its 2025 guidance**, raising the outlook for **total revenue to a range of $3.220 – 3.235 billion** and **adjusted EBITDA to $470 – 480 million**.  **[0001124140_2228511:4]**

Company not found (E2XA34)